Healthcare giant Johnson & Johnson of New Brunswick, NJ, has agreed to buy minimally invasive surgical developer Biopsys Medical of Irvine, CA, in a stock swap valued at $310 million. Biopsys manufactures Mammotome, a biopsy gun that uses a vacuum
Healthcare giant Johnson & Johnson of New Brunswick, NJ, has agreed to buy minimally invasive surgical developer Biopsys Medical of Irvine, CA, in a stock swap valued at $310 million. Biopsys manufactures Mammotome, a biopsy gun that uses a vacuum method for removing breast tissue. The merger is subject to approval by Biopsys shareholders and regulatory authorities.
The amount of Johnson & Johnson stock that will be issued for each Biopsys share will be based on a formula in which $27.55 will be divided by the average closing price per J&J share for each of the 20 trading days preceding the last full trading day prior to a meeting of Biopsys shareholders to approve the merger. Biopsys shares closed at $26.69 the day the merger was announced.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.